GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Dec 31, 2024

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-25-001686General Corporate
Operating cash generation88thOwn-history percentile · N=16
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-112.69% · OPTIONAL · VALID

Revenue growth8thOwn-history percentile · N=12
Evidence method

Yoy · gp.fundamentals.revenue

-1.56% · CORE · VALID

Operating margin88thOwn-history percentile · N=16
Evidence method

Level · gp.fundamentals.operating_margin

-168.16% · CORE · VALID

R&D intensity25thOwn-history percentile · N=16
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

131.52% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=16
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.87% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-74.73%
Current
-112.69%
Delta
-37.95%
Growth Decreased
Previous
0.50%
Current
-1.56%
Delta
-2.07%
Profitability Decreased
Previous
-81.32%
Current
-168.16%
Delta
-86.84%
R And D Intensity Increased
Previous
59.91%
Current
131.52%
Delta
71.61%
Sbc Intensity Increased
Previous
4.48%
Current
6.87%
Delta
2.39%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.